Drug Profile
Research programme: small molecule TYK2 inhibitors - Celgene/Nimbus Therapeutics
Alternative Names: NDI 031232; NDI 031301; NDI 031302; NDI 031407Latest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator Nimbus Therapeutics
- Developer Celgene Corporation; Nimbus Therapeutics
- Class Antineoplastics; Antipsoriatics; Antirheumatics; Small molecules
- Mechanism of Action TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ankylosing spondylitis; Cancer; Crohn's disease; Multiple sclerosis; Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 28 Jun 2022 No recent reports of development identified for preclinical development in Crohn's-disease in USA (PO)
- 28 Jun 2022 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA (PO)